PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19187092-0 2009 L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. Levodopa 0-6 mitogen-activated protein kinase 1 Mus musculus 17-20 19187092-1 2009 In the dopamine-depleted striatum, extracellular signal-regulated kinase (ERK) signaling is implicated in the development of L-DOPA-induced dyskinesia. Levodopa 125-131 mitogen-activated protein kinase 1 Mus musculus 35-72 19187092-1 2009 In the dopamine-depleted striatum, extracellular signal-regulated kinase (ERK) signaling is implicated in the development of L-DOPA-induced dyskinesia. Levodopa 125-131 mitogen-activated protein kinase 1 Mus musculus 74-77 19187092-2 2009 To gain insights on its role in this disorder, we examined the effects of L-DOPA on the state of phosphorylation of ERK and downstream target proteins in striatopallidal and striatonigral medium spiny neurons (MSNs). Levodopa 74-80 mitogen-activated protein kinase 1 Mus musculus 116-119 19187092-4 2009 In 6-hydroxydopamine-lesioned Drd2-EGFP mice, L-DOPA increased the phosphorylation of ERK, mitogen- and stress-activated kinase 1 and histone H3, selectively in EGFP-negative MSNs. Levodopa 46-52 mitogen-activated protein kinase 1 Mus musculus 86-89 19187092-7 2009 The same pattern of activation of ERK signaling was observed in dyskinetic mice, after repeated administration of L-DOPA. Levodopa 114-120 mitogen-activated protein kinase 1 Mus musculus 34-37 19187092-8 2009 Our results demonstrate that in the dopamine-depleted striatum, L-DOPA activates ERK signaling specifically in striatonigral MSNs. Levodopa 64-70 mitogen-activated protein kinase 1 Mus musculus 81-84 17596448-7 2007 Thus, pharmacological inactivation of ERK1/2 achieved using SL327 (alpha-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneacetonitrile), an inhibitor of the mitogen-activated kinase/ERK kinase, MEK, during chronic L-DOPA treatment counteracts the induction dyskinesia. Levodopa 229-235 mitogen-activated protein kinase 1 Mus musculus 38-41 18410512-5 2008 In the murine model of acutely rather than chronically induced LDID, dopamine depletion and levodopa treatment also induced deacetylation of histone H4 and phosphorylation of ERK, but histone H3 exhibited decreased trimethylation and reduced rather than enhanced acetylation. Levodopa 92-100 mitogen-activated protein kinase 1 Mus musculus 175-178 35447917-0 2022 Fucoxanthin Prevents Long-Term Administration l-DOPA-Induced Neurotoxicity through the ERK/JNK-c-Jun System in 6-OHDA-Lesioned Mice and PC12 Cells. Levodopa 46-52 mitogen-activated protein kinase 1 Mus musculus 87-90 16139809-0 2006 ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Levodopa 60-66 mitogen-activated protein kinase 1 Mus musculus 0-3 25164669-7 2014 The behavioral protection of long-term treatment with L-DOPA in AC5-KO mice was preceded by a decrease in the phosphorylation levels of PKA substrates ERK (extracellular signal-regulated kinase) 1/2, MSK1 (mitogen- and stress-activated protein kinase 1), and histone H3, levels of which were all increased in the lesioned striatum of wild-type mice. Levodopa 54-60 mitogen-activated protein kinase 1 Mus musculus 151-154 25233866-2 2014 LID results in part from l-DOPA-induced activation of extracellular signal-regulated kinase (ERK) in the dopamine-denervated striatum. Levodopa 25-31 mitogen-activated protein kinase 1 Mus musculus 54-91 25233866-2 2014 LID results in part from l-DOPA-induced activation of extracellular signal-regulated kinase (ERK) in the dopamine-denervated striatum. Levodopa 25-31 mitogen-activated protein kinase 1 Mus musculus 93-96 31306812-0 2019 Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD. Levodopa 56-62 mitogen-activated protein kinase 1 Mus musculus 136-139 26125041-1 2015 OBJECTIVE: Recent findings have shown that pharmacogenetic manipulations of the Ras-ERK pathway provide a therapeutic means to tackle l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia (LID). Levodopa 134-162 mitogen-activated protein kinase 1 Mus musculus 84-87 26125041-1 2015 OBJECTIVE: Recent findings have shown that pharmacogenetic manipulations of the Ras-ERK pathway provide a therapeutic means to tackle l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia (LID). Levodopa 164-170 mitogen-activated protein kinase 1 Mus musculus 84-87 26125041-2 2015 First, we investigated whether a prolonged l-DOPA treatment differentially affected ERK signaling in medium spiny neurons of the direct pathway (dMSNs) and in cholinergic aspiny interneurons (ChIs) and assessed the role of Ras-GRF1 in both subpopulations. Levodopa 43-49 mitogen-activated protein kinase 1 Mus musculus 84-87 24844602-0 2015 Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia. Levodopa 149-155 mitogen-activated protein kinase 1 Mus musculus 72-109 24844602-0 2015 Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia. Levodopa 149-155 mitogen-activated protein kinase 1 Mus musculus 111-114 24844602-9 2015 Analysis of LTP in animals with unilateral 6-hydroxydopamine lesions (6-OHDA) rendered dyskinetic with chronic L-DOPA treatment reveals a complex, Ras-GRF1 and pathway-independent, apparently stochastic involvement of ERK. Levodopa 111-117 mitogen-activated protein kinase 1 Mus musculus 218-221 24844602-10 2015 CONCLUSIONS: These data not only demonstrate a central role for Ras-ERK signaling in striatal LTP, depotentiation, and LTP restored after L-DOPA treatment but also disclose multifaceted synaptic adaptations occurring in response to dopaminergic denervation and pulsatile administration of L-DOPA. Levodopa 138-144 mitogen-activated protein kinase 1 Mus musculus 68-71 24844602-10 2015 CONCLUSIONS: These data not only demonstrate a central role for Ras-ERK signaling in striatal LTP, depotentiation, and LTP restored after L-DOPA treatment but also disclose multifaceted synaptic adaptations occurring in response to dopaminergic denervation and pulsatile administration of L-DOPA. Levodopa 289-295 mitogen-activated protein kinase 1 Mus musculus 68-71 24650244-0 2014 Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson"s disease mouse model. Levodopa 33-39 mitogen-activated protein kinase 1 Mus musculus 83-86 22539851-2 2012 In the dopamine (DA)-denervated striatum, L-DOPA activates DA D1 receptor(D1R) signaling, including cAMP-dependent protein kinase A (PKA) and extracellular signal-regulated kinase (ERK), two responses associated with LID. Levodopa 42-48 mitogen-activated protein kinase 1 Mus musculus 142-179 22539851-0 2012 Galpha(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Levodopa 128-156 mitogen-activated protein kinase 1 Mus musculus 67-104 22539851-2 2012 In the dopamine (DA)-denervated striatum, L-DOPA activates DA D1 receptor(D1R) signaling, including cAMP-dependent protein kinase A (PKA) and extracellular signal-regulated kinase (ERK), two responses associated with LID. Levodopa 42-48 mitogen-activated protein kinase 1 Mus musculus 181-184 22539851-8 2012 In Gnal+/- mice, the lesion-induced L-DOPA stimulation of cAMP/PKA-mediated phosphorylation of GluA1 Ser845 and DARPP-32 (32 kDa DA- and cAMP-regulated phosphoprotein) Thr34 was dramatically reduced, whereas ERK activation was preserved. Levodopa 36-42 mitogen-activated protein kinase 1 Mus musculus 208-211 22539851-12 2012 In contrast, the persistence of L-DOPA-induced ERK activation in Gnal+/- mice supports its causal role in LID development. Levodopa 32-38 mitogen-activated protein kinase 1 Mus musculus 47-50 21187382-4 2011 After repeated L-DOPA treatment, however, ERK activation diminishes in medium spiny neurons and increases in striatal cholinergic interneurons. Levodopa 15-21 mitogen-activated protein kinase 1 Mus musculus 42-45 21187382-6 2011 Pharmacological blockers of ERK activation inhibit L-DOPA-induced changes in ERK phosphorylation, neuronal excitability, and the behavioral manifestation of LID. Levodopa 51-57 mitogen-activated protein kinase 1 Mus musculus 28-31 21187382-6 2011 Pharmacological blockers of ERK activation inhibit L-DOPA-induced changes in ERK phosphorylation, neuronal excitability, and the behavioral manifestation of LID. Levodopa 51-57 mitogen-activated protein kinase 1 Mus musculus 77-80 21946266-6 2011 Indeed, lesioned mutant mice display physiological L-DOPA-dependent enhancement of striatal D1 receptor/PKA/protein phosphatase-1 and ERK signaling. Levodopa 51-57 mitogen-activated protein kinase 1 Mus musculus 134-137